Sep 23, 2020 / 08:30AM GMT
Operator
Good morning, ladies and gentlemen, and welcome to Allergy Therapeutics' preliminary results conference call and webinar. (Operator Instructions) I will now hand over to Manuel Llobet, CEO of Allergy Therapeutics. Please go ahead.
Manuel Llobet - Allergy Therapeutics plc - CEO & Executive Director
Thank you very much, and very welcome, all of you, and thank you for coming and attending this presentation on our preliminary results for the year ending 30th of June 2020. Clearly, we would have preferred to have this meeting face-to-face as we usually do. We'll miss the individual chitchats that we have after the presentation. But that's the way it is.
So I'm joining today with our Chief Financial Officer, Nick Wykeman; and our Head of Communications Strategy, Alan Bullimore, who will also develop parts of this presentation. So moving to Slide #2, I'll just bring your attention on the standard disclaimer slide, which is included in this presentation for completeness.
And now we can go to Slide #3, where we have an overview of the presentation.
Allergy Therapeutics plc - Special Call Transcript
Mar 04, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers